Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Terns Pharmaceuticals, Inc. (TERN : NSDQ)

• Company Description    Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in development of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases. Terns Pharmaceuticals Inc. is based in FOSTER CITY, Calif. Number of Employees: 41

• Price / Volume Information    Yesterday's Closing Price: $1.50 Daily Weekly Monthly 20 Day Moving Average: 106,488 shares Shares Outstanding: 25.28 (millions) Market Capitalization: $37.92 (millions) Beta: 2.87 52 Week High: $19.97 52 Week Low: $1.45 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -32.43% -23.91% 12 Week -55.36% -50.92% Year To Date -78.78% -72.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1065 EAST HILLSDALE BLVD. SUITE 100 - FOSTER CITY,CA 94404 USA ph: 650-525-5535 fax: - investors@ternspharma.com http://www.ternspharma.com

• General Corporate Information    Officers Senthil Sundaram - Chief Executive Officer and Director David Fellows - Chairman Mark Vignola - Chief Financial Officer Carl Gordon - Director Jeffrey Kindler - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 880881107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/15/22 Share - Related Items Shares Outstanding: 25.28 Most Recent Split Date: (:1) Beta: 2.87 Market Capitalization: $37.92 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.63 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.48 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.25 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 37.50% vs. Previous Quarter: 1.79% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -100.00% ROE 03/31/22 - -62.27 12/31/21 - -651.04 09/30/21 - - ROA 03/31/22 - -29.22 12/31/21 - -27.29 09/30/21 - -27.81 Current Ratio 03/31/22 - 25.00 12/31/21 - 24.48 09/30/21 - 25.94 Quick Ratio 03/31/22 - - 12/31/21 - 24.48 09/30/21 - 25.94 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -5,010.40 12/31/21 - -4,965.00 09/30/21 - - Book Value 03/31/22 - 5.88 12/31/21 - 6.34 09/30/21 - 6.85 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©